Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.

Ucan Gunduz G., Yalcinbayir O., Cekic Ş., Yildiz M., Kilic S. Ş.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, vol.37, no.4, pp.236-240, 2021 (SCI-Expanded) identifier identifier identifier


Purpose: Management of uveitis displays a particular challenge in childhood. This study aims to compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in pediatric noninfectious uveitis that were refractory to conventional immunosuppresives.